The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second ...

The California-based nonprofit founded by the former 23andMe CEO is set to close the $305 million deal in coming weeks.

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron ...

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a ...

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid  Approval based on pivotal results showing improvements in sustained disease remission and ...

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions ...

Anne Wojcicki, co-founder and former CEO of 23andMe, has bid to buy back the genetic testing platform, which was pronounced ...

Regeneron and Sanofi are committed to helping patients in the U.S. who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...